P2RY12
ENSG00000169313
Target class
GPCR
Chromosome
3
Approved drugs
10
Clinical candidates (approved and in development)
13
- Approved drugs
- 10
- ClinGen gene-disease validity
- Definitive
- Clinical candidates (approved and in development)
- 13
- Chemical probe available
- Yes
- Target name
- P2RY12
- Gene name
- Purinergic receptor P2Y12
- Gene symbol
- P2RY12
- Protein name
- P2Y purinoceptor 12 (P2Y12) (ADP-glucose receptor) (ADPG-R) (P2T(AC)) (P2Y(AC)) (P2Y(cyc)) (P2Y12 platelet ADP receptor) (P2Y(ADP)) (SP1999)
- P2Y12
- SP1999
- HORK3
- Gene biotype
- Protein coding
- Gene family
- P2Y receptors
- Target class
- GPCR
- Target type
- Human gene
- Tissues expressed in
- 27
- Highest tissue expression
- 20.6
- Tissue specificity (Gini)
- 0.644
- Tissue specificity (tau)
- 0.891
- KEGG gene identifiers
- hsa:64805
- Protein interaction confidence
- 0.802033
- Protein interaction partners
- 30
- R-HSA-392170
- R-HSA-417957
- R-HSA-418594
- End position
- 151384753
- Start position
- 151336843
- Chromosome
- 3
- Strand
- Reverse
- Cell membrane
- Multi-pass membrane protein .
- PubMed 11196645
- PubMed 12578987
- PubMed 24670650
- PubMed 24784220
- Tissue specificity (tau)
- 0.890758
- Expression inequality (Gini)
- 0.643533
Expression in transcripts per million
- Brain - Spinal cord (cervical c-1)
- 20.6
- Brain - Substantia nigra
- 12.82
- Nerve - Tibial
- 9.35
- Brain - Amygdala
- 8.71
- Brain - Hypothalamus
- 8.06
Expression in transcripts per million
- Brain - Spinal cord (cervical c-1)20.6
- Brain - Substantia nigra12.82
- Nerve - Tibial9.35
- Brain - Amygdala8.71
- Brain - Hypothalamus8.06
- Brain - Caudate (basal ganglia)7.58
- Brain - Nucleus accumbens (basal ganglia)7.39
- Brain - Hippocampus6.97
- Brain - Frontal Cortex (BA9)6.83
- Brain - Anterior cingulate cortex (BA24)5.72
- Brain - Putamen (basal ganglia)5.05
- Spleen2.96
- Adipose - Subcutaneous2.86
- Brain - Cortex2.45
- Brain - Cerebellar Hemisphere2.15
- Adipose - Visceral (Omentum)2.14
- Colon - Sigmoid2.08
- Artery - Coronary1.96
- Small Intestine - Terminal Ileum1.86
- Lung1.73
- Breast - Mammary Tissue1.58
- Esophagus - Muscularis1.55
- Esophagus - Gastroesophageal Junction1.46
- Cervix - Endocervix1.42
- Brain - Cerebellum1.09
And 29 more, listed on the interactive page.
- GO:0007186
- GO:0007193
- GO:0030168
- GO:0050920
- GO:0070527
- GO:1900029
- GO:1904141
- GO:0005886
- GO:0009986
- GO:0016020
- GO:0001621
- GO:0005085
Related records
Trials (968)
- [SOCRATES -Acute Stroke Or Transient IsChaemic Attack TReated With Aspirin or Ticagrelor and Patient OutcomES]
- 1 or 6 Months of Dual Antiplatelet Therapy After Drug-coated Balloon Angioplasty for De-novo Small Coronary Artery Disease
- 1-month DAPT Plus 5-month Ticagrelor Monotherapy Versus 12-month DAPT in Patients With Drug-coated Balloon
- 24-month Ticagrelor-based Dual-antiplatelet Therapy Versus Clopidogrel-based Dual-antiplatelet theRapy aftEr 12 Months of DrUg-eluting Stent Implantation in High isChEmic Risk Patients: P-REDUCE Trial
- 3 Months Versus 12 Months Dual Antiplatelet Therapy After Drug-eluting Stent Implantation in STEMI
- 75 or 150 mg Clopidogrel Maintenance Doses Following PCI (ISAR-CHOICE-2)
- A 30 Day Study to Evaluate Efficacy and Safety of Pre-hospital vs. In-hospital Initiation of Ticagrelor Therapy in STEMI Patients Planned for Percutaneous Coronary Intervention (PCI)
- A Clinical Study of Safety and P2Y12 Receptor Inhibition Effects of Ticagrelor and Clopidogrel in Vietnamese Patient
- A Clinical Study to Assess the Effect of Clopidogrel on the Pharmacokinetics of Selexipag and Its Active Metabolite in Healthy Male Subjects
- A Clinical Trial Comparing Cangrelor to Clopidogrel Standard Therapy in Subjects Who Require Percutaneous Coronary Intervention (PCI) (CHAMPION PHOENIX)
- A Clinical Trial of Antiplatelets in Psoriasis
- A Clinical Trial to Demonstrate the Efficacy of Cangrelor
- A Comparative Study of Selatogrel (ACT-246475) Formulations in Healthy Subjects
- A Comparison of Antiplatelet Therapies in Asian Subjects With Acute Coronary Syndrome
- A Comparison of Prasugrel (CS-747) and Clopidogrel in Acute Coronary Syndrome Subjects Who Are to Undergo Percutaneous Coronary Intervention
- A Comparison of Prasugrel and Clopidogrel in Acute Coronary Syndrome Subjects
- A Comparison of Prasugrel at PCI or Time of Diagnosis of Non-ST Elevation Myocardial Infarction
- A Comparison of Ticagrelor (AZD6140) and Clopidogrel in Patients With Acute Coronary Syndrome
- A Drug-drug Interaction Study of YZJ-1139 Tablets and Ticagrelor Tablets in Healthy Subjects
- A EUROpean Randomized Study on Blood-thinners and Cholesterol-lowering Treatments to Prevent Future Vascular Events in People With Covert Brain Infarcts (CBI)
Drugs (19)
- Adenosine diphosphate
- Cangrelor Purinergic receptor P2Y12 antagonist; Purinergic receptor P2Y12 inhibitor
- Cangrelor tetrasodium Purinergic receptor P2Y12 antagonist
- Clopidogrel Purinergic receptor P2Y12 antagonist
- Clopidogrel besilate Purinergic receptor P2Y12 antagonist
- Clopidogrel bisulfate Purinergic receptor P2Y12 antagonist
- Clopidogrel hydrobromide Purinergic receptor P2Y12 antagonist
- Clopidogrel hydrochloride Purinergic receptor P2Y12 antagonist
- Elinogrel Purinergic receptor P2Y12 antagonist
- Elinogrel potassium Purinergic receptor P2Y12 antagonist
- Prasugrel Purinergic receptor P2Y12 antagonist
- Prasugrel besylate Purinergic receptor P2Y12 antagonist
- Prasugrel hydrochloride Purinergic receptor P2Y12 antagonist
- Regrelor Purinergic receptor P2Y12 antagonist
- Regrelor disodium Purinergic receptor P2Y12 antagonist
- Selatogrel Purinergic receptor P2Y12 antagonist
- Ticagrelor Purinergic receptor P2Y12 negative allosteric modulator
- Ticlopidine Purinergic receptor P2Y12 antagonist
- Ticlopidine hydrochloride Purinergic receptor P2Y12 antagonist